Similar articles for PMID: 19070762

Year	Number of Results
1984	1
1995	1
2004	1
2005	14
2006	15
2007	15
2008	21
2009	26
2010	23
2011	13
2012	19
2013	15
2014	15
2015	9
2016	14
2017	6
2018	5
2019	11
2020	8
2021	8
2022	7
2023	0

1

Bisphosphonate-induced osteonecrosis of the jaws, bone markers, and a hypothesized candidate gene.

Lehrer S, Montazem A, Ramanathan L, Pessin-Minsley M, Pfail J, Stock RG, Kogan R. Lehrer S, et al. J Oral Maxillofac Surg. 2009 Jan;67(1):159-61. doi: 10.1016/j.joms.2008.09.015. J Oral Maxillofac Surg. 2009. PMID: 19070762

2

Normal serum bone markers in bisphosphonate-induced osteonecrosis of the jaws.

Lehrer S, Montazem A, Ramanathan L, Pessin-Minsley M, Pfail J, Stock RG, Kogan R. Lehrer S, et al. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008 Sep;106(3):389-91. doi: 10.1016/j.tripleo.2008.01.033. Epub 2008 Jun 13. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008. PMID: 18554944

3

Changes in serological bone turnover markers in bisphosphonate induced osteonecrosis of the jaws: A case control study.

Demircan S, Isler SC. Demircan S, et al. Niger J Clin Pract. 2020 Feb;23(2):154-158. doi: 10.4103/njcp.njcp_374_19. Niger J Clin Pract. 2020. PMID: 32031088 Clinical Trial.

4

Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment.

Marx RE, Cillo JE Jr, Ulloa JJ. Marx RE, et al. J Oral Maxillofac Surg. 2007 Dec;65(12):2397-410. doi: 10.1016/j.joms.2007.08.003. J Oral Maxillofac Surg. 2007. PMID: 18022461

5

Clinical investigation of C-terminal cross-linking telopeptide test in prevention and management of bisphosphonate-associated osteonecrosis of the jaws.

Kunchur R, Need A, Hughes T, Goss A. Kunchur R, et al. J Oral Maxillofac Surg. 2009 Jun;67(6):1167-73. doi: 10.1016/j.joms.2009.02.004. J Oral Maxillofac Surg. 2009. PMID: 19446200 Clinical Trial.

6

Bisphosphonate-associated osteonecrosis: a clinician's reference to patient management.

Grewal VS, Fayans EP. Grewal VS, et al. Todays FDA. 2008 Aug;20(8):38-41, 43-6. Todays FDA. 2008. PMID: 18767452

7

Importance of microcracks in etiology of bisphosphonate-related osteonecrosis of the jaw: a possible pathogenetic model of symptomatic and non-symptomatic osteonecrosis of the jaw based on scanning electron microscopy findings.

Hoefert S, Schmitz I, Tannapfel A, Eufinger H. Hoefert S, et al. Clin Oral Investig. 2010 Jun;14(3):271-84. doi: 10.1007/s00784-009-0300-6. Epub 2009 Jun 18. Clin Oral Investig. 2010. PMID: 19536569

8

Osteonecrosis of the jaws and bisphosphonate treatment in cancer patients.

Wutzl A, Eisenmenger G, Hoffmann M, Czerny C, Moser D, Pietschmann P, Ewers R, Baumann A. Wutzl A, et al. Wien Klin Wochenschr. 2006 Aug;118(15-16):473-8. doi: 10.1007/s00508-006-0644-8. Wien Klin Wochenschr. 2006. PMID: 16957978

9

CTX biochemical marker of bone metabolism. Is it a reliable predictor of bisphosphonate-associated osteonecrosis of the jaws after surgery? Part II: a prospective clinical study.

Lee CY, Suzuki JB. Lee CY, et al. Implant Dent. 2010 Feb;19(1):29-38. doi: 10.1097/ID.0b013e3181cec8bc. Implant Dent. 2010. PMID: 20147814 Clinical Trial.

10

Oral bisphosphonate-related osteonecrosis of the jaws: favorable outcome after bisphosphonate holiday.

Kwon YD, Kim YR, Choi BJ, Lee DW, Kim DY. Kwon YD, et al. Quintessence Int. 2009 Apr;40(4):277-8. Quintessence Int. 2009. PMID: 19417871

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

220 results

Results by year